Publications

Chou, KL, JJ Elm, CL Wielinski, DK Simon, MJ Aminoff, CW Christine, GS Liang, RA Hauser, L Sudarsky, and . 2017. “Factors Associated With Falling in Early, Treated Parkinson’s Disease: The NET-PD LS1 Cohort. J Neurol Sci 2017;377:137-143.”. J Neurol Sci.

Fernandez, HH, SA Factor, RA Hauser, J Jimenez-Shahed, and . 2017. “Randomized Controlled Trial of Deutetrabenazine for Tardive Dyskinesia: The ARM-TD Study. Neurology 2017;88:2003-2010.”. Neurology.

Olanow, CW, K Kieburtz, M Leinonen, N Giladi, RA Hauser, OS Klepiskaya, DL Kreitzman, et al. 2017. “A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease. Mov Disord 2017;32:783-789.”. Mov Disord.

Simon, DK, C Wu, BC Tilley, K Lohmann, C Klein, H Payami, AM Wills, et al. 2017. “Caffeine, Creatine, GRIN2A and Parkinson’s Disease Progression. J Neurol Sci 2017;375:355-359.”. J Neurol Sci.

Hauser, RA, SA Factor, SR Marder, MA Knesevich, PM Ramirez, , J Burke, GS Liang, and CF O’Brien. 2017. “KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry 2017;174:476-484.”. Am J Psychiatry.

Stocchi, F, O Rascol, RA Hauser, S Huyck, A Tzontcheva, R Capece, TW Ho, et al. 2017. “Randomized Trial of Preladenant, Given As Monotherapy, in Patients With Early Parkinson Disease. Neurology 2017;88:2198-2206.”. Neurology.

White, WB, RA Hauser, GJ Rowse, A Ziemann, and LA Hewitt. 2017. “Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. Am J Cardiol 2017;119:1111-1115.”. Am J Cardiol.

Tetrud, J, P Nausieda, D Kreitzman, GS Liang, A Nieves, AP Duker, RA Hauser, et al. 2017. “Conversion to Carbidopa and Levodopa Extended-Release (IPX066) Followed by Its Extended Use in Patients Previously Taking Controlled-Release Carbidopa-Levodopa for Advanced Parkinson’s Disease. J Neurol Sci 2017;373:116-123.”. J Neurol Sci.

Schapira, AH, SH Fox, RA Hauser, J Jankovic, WH Jost, C Kennedy, J Kulisevsky, R Pahwa, W Poewe, and R Anand. 2017. “Assessment of Safety and Efficacy of Safinamide As a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol 2017;74:216-224.”. JAMA Neurol.

Hauser, RA, R Li, A Perez, X Ren, D Weintraub, J Elm, JL Goudreau, et al. 2017. “NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure Is Associated With Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.”. J Parkinsons Dis.